Schematic diagram of the mass spectrometry method and experimental flow for detecting the pharmacokinetic profile and tissue distribution of the 3 EGFR-TKIs. (IMAGE)
Caption
In this study, an UPLC-MS/MS method with specificity and accuracy was established to simultaneously quantify aumolertinib, osimertinib, gefitinib and their major metabolites (left). By using this method, we found that the bioavailability and tissue distribution features of aumolertinib were superior to those of osimertinib and gefitinib in mice model (middle) and in the plasma of EGFR mutation positive NSCLC patients (right).
Credit
Not applicable
Usage Restrictions
Not applicable
License
Original content